Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases
AM Di Giacomo, V Chiarion-Sileni, M Del Vecchio… - Clinical Cancer …, 2021 - AACR
… and ipilimumab plus nivolumab in melanoma brain metastases. We report … NIBIT-M2 study,
the first phase III trial comparing these regimens with fotemustine in patients with melanoma …
the first phase III trial comparing these regimens with fotemustine in patients with melanoma …
[HTML][HTML] … -year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II …
AM Di Giacomo, PA Ascierto, P Queirolo, L Pilla… - Annals of …, 2015 - Elsevier
… phase III, NIBIT-M2 study is randomizing MM patients with brain … of ipilimumab in melanoma
patients with brain metastases, in … -PD-1 mAb nivolumab, the NIBIT-M2 study has been lately …
patients with brain metastases, in … -PD-1 mAb nivolumab, the NIBIT-M2 study has been lately …
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
C Maccalli, D Giannarelli, F Capocefalo, L Pilla… - …, 2016 - Taylor & Francis
… Along this line the phase III NIBIT-M2 trial, comparing the … and fotemustine in patients with
advanced melanoma (NIBIT-M1): … Three-year follow-up of advanced melanoma patients who …
advanced melanoma (NIBIT-M1): … Three-year follow-up of advanced melanoma patients who …
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial
AM Di Giacomo, A Covre, F Finotello, D Rieder… - Clinical Cancer …, 2019 - AACR
… mg/m 2 /day in case no DLTs were observed at 30 mg/m 2 /day… also in the initial six patients
treated at 45 mg/m 2 /day, the … on melanoma cells induced by treatment in our NIBIT-M4 …
treated at 45 mg/m 2 /day, the … on melanoma cells induced by treatment in our NIBIT-M4 …
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.
AM Di Giacomo, A Covre, F Finotello, D Rieder… - 2019 - ascopubs.org
… of advanced melanoma. Methods: Patients with unresectable Stage III/IV melanoma
received escalating doses of guadecitabine 30, 45 or 60 mg/m 2 subcutaneously on Days 1…
received escalating doses of guadecitabine 30, 45 or 60 mg/m 2 subcutaneously on Days 1…
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial
TM Rosaria Noviello, AM Di Giacomo, FP Caruso… - medRxiv, 2023 - medrxiv.org
… escalation, single-center NIBIT-M4 study, enrolled pre-treated or untreated patients with
unresectable Stage III or IV melanoma, to receive guadecitabine 30, 45, or 60 mg/m 2 /day sc on …
unresectable Stage III or IV melanoma, to receive guadecitabine 30, 45, or 60 mg/m 2 /day sc on …
… ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 …
AM Di Giacomo, VC Sileni, M Del Vecchio… - Annals of …, 2020 - annalsofoncology.org
… melanoma (MM) patients (pts) with BM for over two decades. The Italian Network for Tumor
Biotherapy (NIBIT… We here report the results of the primary analysis of the NIBIT-M2 study, the …
Biotherapy (NIBIT… We here report the results of the primary analysis of the NIBIT-M2 study, the …
A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.
AM Di Giacomo, PA Ascierto, E Fonsatti… - Journal of Clinical …, 2011 - ascopubs.org
… The Italian Network for Tumor Biotherapy (NIBIT) … NIBIT-M1 is a phase II, open-label,
single arm study that enrols unresectable stage III or IV cutaneous melanoma pts in seven NIBIT …
single arm study that enrols unresectable stage III or IV cutaneous melanoma pts in seven NIBIT …
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
TMR Noviello, AM Di Giacomo, FP Caruso… - Nature …, 2023 - nature.com
… escalation, single-center NIBIT-M4 study, enrolled pre-treated or untreated patients with
unresectable Stage III or IV melanoma, to receive guadecitabine 30, 45, or 60 mg/m 2 /day sc on …
unresectable Stage III or IV melanoma, to receive guadecitabine 30, 45, or 60 mg/m 2 /day sc on …
[HTML][HTML] … plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
AM Di Giacomo, V Chiarion-Sileni… - European Journal of …, 2024 - Elsevier
… NIBIT-M2 study provide the longest evidence of the efficacy of ipilimumab plus nivolumab in
melanoma patients … year primary analysis of the NIBIT-M2 study demonstrated that treatment …
melanoma patients … year primary analysis of the NIBIT-M2 study demonstrated that treatment …
相关搜索
- ipilimumab in melanoma patients nibit m2
- fotemustine in patients nibit m2
- melanoma patients nibit m4 study
- melanoma patients brain metastases
- melanoma patients clinical outcome
- malignant melanoma patients
- melanoma patients compassionate use setting
- 7 year outcomes nibit m2
- melanoma patients tumor biotherapy
- multicenter phase nibit m2
- quality of life nibit m2
- primary analysis nibit m2
- ipilimumab in melanoma patients clinical activity
- melanoma patients retrospective analysis of data
- melanoma patients italian network
- melanoma patients phase 2 trial